FORMA THERAPEUTICS HOLDINGS (FMTX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:FMTX • US34633R1041

20.01 USD
+0.03 (+0.15%)
At close: Oct 13, 2022
20.01 USD
0 (0%)
After Hours: 10/13/2022, 8:24:26 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, FMTX scores 2 out of 10 in our fundamental rating. FMTX was compared to 523 industry peers in the Biotechnology industry. FMTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. FMTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • FMTX had negative earnings in the past year.
FMTX Yearly Net Income VS EBIT VS OCF VS FCFFMTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 0 -50M -100M -150M

1.2 Ratios

Industry RankSector Rank
ROA -40.02%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FMTX Yearly ROA, ROE, ROICFMTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 0 20 -20

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FMTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FMTX Yearly Profit, Operating, Gross MarginsFMTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 0 -10 -20 -30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • The number of shares outstanding for FMTX has been increased compared to 1 year ago.
  • There is no outstanding debt for FMTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FMTX Yearly Shares OutstandingFMTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 10M 20M 30M 40M
FMTX Yearly Total Debt VS Total AssetsFMTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 200M 400M 600M

2.2 Solvency

  • FMTX has an Altman-Z score of 8.17. This indicates that FMTX is financially healthy and has little risk of bankruptcy at the moment.
  • FMTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.17
ROIC/WACCN/A
WACCN/A
FMTX Yearly LT Debt VS Equity VS FCFFMTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 0 200M 400M 600M

2.3 Liquidity

  • FMTX has a Current Ratio of 12.74. This indicates that FMTX is financially healthy and has no problem in meeting its short term obligations.
  • A Quick Ratio of 12.74 indicates that FMTX has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 12.74
Quick Ratio 12.74
FMTX Yearly Current Assets VS Current LiabilitesFMTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • FMTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -32.01%.
EPS 1Y (TTM)-32.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • FMTX is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -2.50% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-17.37%
EPS Next 2Y-1.79%
EPS Next 3Y0.88%
EPS Next 5Y-2.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FMTX Yearly Revenue VS EstimatesFMTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2022 2023 2024 2025 2026 50M 100M 150M
FMTX Yearly EPS VS EstimatesFMTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FMTX. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FMTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FMTX Price Earnings VS Forward Price EarningsFMTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -2.98
FMTX Per share dataFMTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.79%
EPS Next 3Y0.88%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • FMTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

FORMA THERAPEUTICS HOLDINGS

NASDAQ:FMTX (10/13/2022, 8:24:26 PM)

After market: 20.01 0 (0%)

20.01

+0.03 (+0.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05
Earnings (Next)11-11
Inst Owners0.69%
Inst Owner Change0%
Ins Owners5.32%
Ins Owner Change0%
Market Cap957.53M
Revenue(TTM)N/A
Net Income(TTM)-190.16M
Analysts75
Price Target21.01 (5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB N/A
EV/EBITDA -2.98
EPS(TTM)-4
EYN/A
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS8.66
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.02%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.74
Quick Ratio 12.74
Altman-Z 8.17
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-32.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.57%
EPS Next Y-17.37%
EPS Next 2Y-1.79%
EPS Next 3Y0.88%
EPS Next 5Y-2.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

FORMA THERAPEUTICS HOLDINGS / FMTX FAQ

Can you provide the ChartMill fundamental rating for FORMA THERAPEUTICS HOLDINGS?

ChartMill assigns a fundamental rating of 2 / 10 to FMTX.


What is the valuation status of FORMA THERAPEUTICS HOLDINGS (FMTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to FORMA THERAPEUTICS HOLDINGS (FMTX). This can be considered as Overvalued.


What is the profitability of FMTX stock?

FORMA THERAPEUTICS HOLDINGS (FMTX) has a profitability rating of 1 / 10.


Is the dividend of FORMA THERAPEUTICS HOLDINGS sustainable?

The dividend rating of FORMA THERAPEUTICS HOLDINGS (FMTX) is 0 / 10 and the dividend payout ratio is 0%.